Utilization and Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists in Posttransplant Diabetes Mellitus in Kidney Transplant Recipients
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70354 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, 2025. Verfasst von Garyn Metoyer und 10 weiteren Autor:innen. Beteiligte Einrichtung: NYU Langone Department of Surgery, New York, New York, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Glucagon-Like Peptide-1 Receptor Agonists, Postoperative Complications, Hypoglycemic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: NIDDK NIH HHS, National Institute of Allergy and Infectious Diseases, Mid-America Transplant/Jane A. Beckman Endowed Chair in Transplantation.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Glucagon‐like peptide‐1 receptor agonists (GLP1RA) provide survival benefits in people with diabetes, including kidney transplant (KT) recipients with pre‐existing diabetes. Post‐transplant diabetes mellitus (PTDM) is common, but the benefits of GLP1RAs remain undefined in this population. We aim to describe current usage practices and outcomes in PTDM.
Methods
We used USRDS and Medicare claims data (2013–2022) to conduct a drug utilization profile of GLP1RA among 7681 first‐time adult KT recipients with PTDM. We used survival analysis to estimate GLP1RA initiation incidence and associated patient, graft, and safety outcomes.
Results
A total of 430 adult KT recipients with PTDM were prescribed GLP1RA. Dulaglutide was the most commonly prescribed medication (46.1%). The 5‐year cumulative incidence of GLP‐1 receptor agonists prescription was 9.8%. Median (interquartile range) time from PTDM diagnosis to first prescription was 1.7 (0.6, 3.4) years. GLP1RA use was not associated with a difference in the risk of mortality or graft failure but was associated with a 1.80‐fold (95% confidence interval [CI]: 1.11–2.91) increased risk of diabetic retinopathy. No increased risk of pancreatitis, biliary complications, or medullary thyroid cancer were identified.
Conclusions
GLP1RA use in KT recipients with PTDM was not associated with graft or patient survival, though longer follow‐up is necessary. GLP1RA use was associated with an increased risk of diabetic retinopathy, and care should be taken when initiating these agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NYU Langone Department of Surgery, New York, New York, USA.
- Saint Louis University Department of Medicine, St. Louis, Missouri, USA.
- NYU Langone Department of Population Health, New York, New York, USA.
- NYU Langone Department of Medicine, New York, New York, USA.
ORCID-Profile: Garyn Metoyer, Harriz Z Whiteson, Yusi Chen, Yiting Li, Chenxi Gao, Gayathri Menon, Sunjae Bae, Krista L Lentine, Dorry L Segev, Mara A McAdams-DeMarco, Babak J Orandi
Förderung
- NIDDK NIH HHS
- National Institute of Allergy and Infectious Diseases
- Mid-America Transplant/Jane A. Beckman Endowed Chair in Transplantation
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Metoyer, G., Whiteson, H. Z., Chen, Y., Li, Y., Gao, C., Menon, G., Bae, S., Lentine, K. L., Segev, D. L., McAdams-DeMarco, M. A., & Orandi, B. J. (2025). Utilization and Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists in Posttransplant Diabetes Mellitus in Kidney Transplant Recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.70354
Vancouver
Metoyer G, Whiteson HZ, Chen Y, Li Y, Gao C, Menon G, et al. Utilization and Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists in Posttransplant Diabetes Mellitus in Kidney Transplant Recipients. Clinical Transplantation. 2025. doi:10.1111/ctr.70354
BibTeX
@article{Metoyer2025,
author = {Metoyer, Garyn and Whiteson, Harriz Z and Chen, Yusi and Li, Yiting and Gao, Chenxi and Menon, Gayathri and Bae, Sunjae and Lentine, Krista L and Segev, Dorry L and McAdams-DeMarco, Mara A and Orandi, Babak J},
title = {Utilization and Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists in Posttransplant Diabetes Mellitus in Kidney Transplant Recipients},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70354}
}
EUVIMED